CYP1A2抗体;CYP1A2 Antibody—艾普蒂

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane: Human hepatocellular carcinoma tissue, Primary antibody: P12016(CYP1A2 Antibody) at dilution 1/440, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 3 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using P12016(CYP1A2 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain  tissue using P12016(CYP1A2 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The CYP1A2 antibody is a crucial tool for studying the cytochrome P450 1A2 enzyme, a member of the cytochrome P450 superfamily involved in metabolizing xenobiotics and endogenous compounds. CYP1A2 is primarily expressed in the liver and plays a key role in the oxidation of numerous drugs (e.g., caffeine, clozapine) and procarcinogens (e.g., heterocyclic amines). This enzyme's activity is influenced by genetic polymorphisms, environmental factors (e.g., smoking), and drug interactions, impacting individual responses to therapeutics and disease risks.

CYP1A2 antibodies are widely used in research to detect enzyme expression, localization, and regulation via techniques like Western blotting, immunohistochemistry (IHC), and ELISA. They help investigate CYP1A2 induction by aryl hydrocarbon receptor (AhR) ligands (e.g., polycyclic aromatic hydrocarbons) or inhibition by compounds like fluvoxamine. Studies using these antibodies have linked altered CYP1A2 levels to conditions such as liver cancer, obesity, and metabolic disorders.

High-quality CYP1A2 antibodies are validated for specificity, often using knockout cell lines or tissues to confirm minimal cross-reactivity with related isoforms (e.g., CYP1A1). Their application advances understanding of drug metabolism, toxicity mechanisms, and personalized medicine strategies targeting CYP1A2 variability.